South Korea FSS Announces Biotech Disclosure Reform on the 30th
South Korea's Financial Supervisory Service (FSS) announced on the 30th a comprehensive reform of disclosure requirements for pharmaceutical and biotech companies. The new rules mandate that firms quantify core valuation assumptions—including clinical trial success rates and regulatory approval
GateCryptoFrontier·07-30 04:23









